201 related articles for article (PubMed ID: 33631080)
1. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine.
Watle SV; Næss LM; Tunheim G; Caugant DA; Wisløff T
Hum Vaccin Immunother; 2021 Aug; 17(8):2777-2787. PubMed ID: 33631080
[TBL] [Abstract][Full Text] [Related]
2. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
Si S; Zomer E; Fletcher S; Lee J; Liew D
Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.
De Wals P; Zhou Z
Pediatr Infect Dis J; 2017 Jul; 36(7):e203-e207. PubMed ID: 28027288
[TBL] [Abstract][Full Text] [Related]
5. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China.
Zhang H; Zhang H; Fang H
Hum Vaccin Immunother; 2024 Dec; 20(1):2313872. PubMed ID: 38348600
[TBL] [Abstract][Full Text] [Related]
9. Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.
Ohm M; Hahné SJM; van der Ende A; Sanders EAM; Berbers GAM; Ruijs WLM; van Sorge NM; de Melker HE; Knol MJ
Clin Infect Dis; 2022 Jul; 74(12):2173-2180. PubMed ID: 34525199
[TBL] [Abstract][Full Text] [Related]
10. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
[TBL] [Abstract][Full Text] [Related]
11. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
[TBL] [Abstract][Full Text] [Related]
12. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
Trotter CL; Edmunds WJ
BMJ; 2002 Apr; 324(7341):809. PubMed ID: 11934772
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR
JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590
[TBL] [Abstract][Full Text] [Related]
15. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
Pharmacoecon Open; 2024 May; ():. PubMed ID: 38780884
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
17. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction.
Villena R; Valenzuela MT; Bastías M; Santolaya ME
Vaccine; 2022 Jan; 40(4):666-672. PubMed ID: 34996641
[TBL] [Abstract][Full Text] [Related]
18. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
[TBL] [Abstract][Full Text] [Related]
19. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
20. Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005: demand, supply and seasonality.
Lorick SA; Fishbein D; Weintraub E; Wortley PM; Lee GM; Zhou F; Davis R
BMC Infect Dis; 2009 Nov; 9():175. PubMed ID: 19887009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
